PRESENCE OF INTERLEUKIN-2 IN URINE OF SUPERFICIAL BLADDER-CANCER PATIENTS AFTER INTRAVESICAL TREATMENT WITH BACILLUS CALMETTE-GUERIN

被引:32
作者
DEJONG, WH
DEBOER, EC
VANDERMEIJDEN, APM
VEGT, P
STEERENBERG, PA
DEBRUYNE, FMJ
RUITENBERG, EJ
机构
[1] UNIV HOSP NIJMEGEN,DEPT UROL,NIJMEGEN,NETHERLANDS
[2] GROOTE ZIEKENGASTHUIS,DEPT UROL,HERTOGENBOSCH,NETHERLANDS
[3] ST ELIZABETH HOSP,DEPT UROL,LEIDERDORP,NETHERLANDS
关键词
D O I
10.1007/BF01744734
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Urine samples were obtained from patients with superficial bladder cancer after immunotherapy with bacillus Calmette-Guérin (BCG). The patients were repeatedly (once a week for 6 consecutive weeks) treated with intravesical administration of approximately 5 × 108 culturable particles of BCG. Some patients received more than six BCG instillations. The urine samples were investigated for the presence of interleukin-2 (IL-2) in an in vitro bioassay using a murine cytotoxic T cell line (CTTL-16) that shows IL-2-dependent growth. Preliminary experiments indicated the presence of inhibitory factors in the urine. This inhibitory activity was abolished after 24 h dialysis. In a neutralization assay with both polyvalent and monoclonal anti-(human IL-2) antibody it was demonstrated that there was indeed IL-2 in the urine samples. In 8 of 11 patients the presence of IL-2 in the urine was demonstrated. The IL-2 production was directly related to the BCG administration as samples obtained just before the BCG instillation were always negative. In IL-2-positive samples a maximum level of IL-2 was observed between 2 h and 6 h after the BCG instillation. In urine samples obtained 24 h after the BCG IL-2 was not detected. In most patients the urine became positive after the third or fourth BCG instillation © 1990 Springer-Verlag.
引用
收藏
页码:182 / 186
页数:5
相关论文
共 28 条
[1]  
BOHLE A, 1989, 1989 C NEW TRENDS UR, P40
[2]  
COE JE, 1966, IMMUNOLOGY, V10, P127
[3]  
DEBRUYNE FMJ, 1988, UROLOGY, V31, P20
[4]  
DEJONG WH, 1986, VIRCHOWS ARCH B, V50, P249
[5]   EXPERIMENTAL SCREENING OF BCG PREPARATIONS PRODUCED FOR CANCER-IMMUNOTHERAPY - SAFETY AND IMMUNOSTIMULATING AND ANTITUMOR-ACTIVITY OF 4 CONSECUTIVELY PRODUCED BATCHES [J].
DEJONG, WH ;
STEERENBERG, PA ;
KREEFTENBERG, JG ;
TIESJEMA, RH ;
KRUIZINGA, W ;
JANSEN, LMV ;
RUITENBERG, EJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1984, 17 (01) :18-27
[6]  
DEJONG WH, 1987, RES MONOGR IMMUNOL, V11, P283
[7]   HISTOPATHOLOGY OF BCG AND THIOTEPA TREATED BLADDERS [J].
GUINAN, P ;
SHAW, M ;
RAY, V .
UROLOGICAL RESEARCH, 1986, 14 (04) :211-215
[8]  
HAAF EO, 1985, WORL J UROL, V3, P76
[9]   DETECTION OF INTERLEUKIN-2 IN THE URINE OF PATIENTS WITH SUPERFICIAL BLADDER-TUMORS AFTER TREATMENT WITH INTRAVESICAL BCG [J].
HAAFF, EO ;
CATALONA, WJ ;
RATLIFF, TL .
JOURNAL OF UROLOGY, 1986, 136 (04) :970-974
[10]  
HANNA MG, 1972, J NATL CANCER I, V48, P1441